DNLI
Denali Therapeutics Inc. Common Stock
NasdaqGSUSDEQUITY
DELAYED
Last price
24.92
▼ 0.03 (0.12%)
MARKET · —
Price
Open
25.10
Prev close
24.95
Day high
25.29
Day low
24.60
Volume
680.99K
Market cap
—
P/E (TTM)
—
52W range
12.58 – 27.30
Trailing performance
Returnvs SPY
1W
+2.13%
+3.5%
1M
+6.40%
+2.7%
3M
+29.12%
+26.0%
6M
+23.43%
+12.4%
YTD
+50.94%
+38.6%
1Y
+71.74%
+51.7%
3Y
+5.86%
-68.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
24.84
+0.32% from price
SMA 20
24.43
+2.02% from price
SMA 50
24.32
+2.45% from price
SMA 100
22.00
+13.26% from price
SMA 200
20.46
+21.77% from price
EMA 12
24.73
+0.79% from price
EMA 26
24.43
+2.03% from price
EMA 50
23.80
+4.70% from price
RSI (14)
54.2
Neutral
MACD (12,26,9)
0.30
Hist 0.03
ATR (14)
0.88
3.52% of price
Realised vol 30D
58.3%
Annualised
Bollinger upper
25.73
20, 2σ
Bollinger lower
23.12
20, 2σ
50 / 200 cross
Golden
24.32 vs 20.46
Trend bias
Above 200
+21.77%
Risk profile
Beta vs SPY
1.44
More volatile than market
Correlation to SPY
0.33
Loosely linked
Realised vol 30D
58.3%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-20.5%
Peak to trough
Max drawdown 5Y
-79.5%
Peak to trough
ATR 14
0.88
3.52% of price
Beta (reported)
—
5Y monthly, from filing
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
DNLI Stock Gains 33.1% in Three Months: Buy, Sell or Hold the Stock?
Zacks · 2d ago
Should You Buy, Sell or Hold Biogen Stock After a 9% Rise in a Month?
Zacks · 2d ago
Denali Therapeutics (DNLI) Q2 2026 Earnings Call Transcript
Motley Fool · 9d ago
UBS Adjusts Price Target on Denali Therapeutics to $34 From $25, Maintains Buy Rating
MT Newswires · 15d ago
Denali Therapeutics Inc. Q2 2026 Earnings Call Summary
Moby · 15d ago
Wedbush Adjusts PT on Denali Therapeutics to $27 From $26, Maintains Outperform Rating
MT Newswires · 15d ago
Denali Therapeutics Q2 Earnings Call Highlights
MarketBeat · 16d ago
Denali Therapeutics Inc. (DNLI) Reports Q2 Loss, Tops Revenue Estimates
Zacks · 16d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.